PharmaEngine, Inc. announced the first patient was dosed in Phase I Trial of Pep07 for Hematological Cancers. Cause of occurrence: (1) PEP07 is a checkpoint kinase 1 (Chk1) inhibitor featuring high kinase selectivity, brain penetrating and oral bioavailability which targets the DNA Damage Response (DDR) pathway. PEP07 has demonstrated significant single-agent activity and combination potential with standard treatments in preclinical model.

Currently, PharmaEngine is conducting a Phase 1 clinical trial in Australia and Taiwan for hematological cancers. Announce the first patient was dosed. According to the license and collaboration agreement with Sentinel Oncology, UK-based partner, PharmaEngine will make a milestone payment.

(2) New drug development requires long process, vast investments and with no guarantee in success which may pose investment risks. The investors are advised to exercise caution and conduct thorough evaluation.